photo walkheader_zpsd5bunpmi.png

Author Archives: pancreatica

Unfolding: Gemcitabine + Abraxane + Cisplatin for Stage 4 Pancreatic Cancer

Since the mid-1990s, teams affiliated with Dr. Daniel Von Hoff have ushered in two of the three key advances in the first-line treatment of advanced pancreatic cancer (ductal adenocarcinoma of the pancreas). This includes seminal work from a research institute affiliated with the University of Texas at San Antonio on the development of gemcitabine for […]

FOLFIRINOX vs. Gemcitabine plus Abraxane for Advanced Pancreatic Cancer

Every person is different; every situation is different; every cancer is different. So, the decision about which treatment is right for an individual patient with pancreatic cancer (ductal adenocarcinoma of the pancreas) by their health care team is highly complex. Here we present the work of published research that examines factors related to two of […]

Neoadjuvant Therapy in Stage 3 Pancreatic Cancer Confers Survival Advantage

In a certain sense, treatment selection by professionals is easier in early or late stage pancreatic cancer (ductal adenocarcinoma of the pancreas) because the options tend to be narrower: early yields surgery; late leans toward chemotherapy alone. The middle stages II and III, or locally advanced, potentially resectable pancreatic cancer, etc. tend to be more […]

Facebook
Facebook